Praxis Precision Medicines gets JPMorgan Overweight rating, $700 price target
PRAX•JPMorgan initiated coverage of Praxis Precision Medicines with an Overweight rating and a $700 price target.
Related News
Vehicles from Geely brands to come with Google built-in services outside China
GOOGL•
South Africa dismisses appeals against exploration in TotalEnergies Block 3B/4B
TTE•
West Fraser Timber Co. Ltd.: RBC cuts target price to $81 from $83
WFG•
Hilton Grand Vacations: Jefferies cuts target price to $41 from $51
HGV•
Misto Holdings clarifies KRW 72.68 billion Acushnet share sale value is before withholding tax
GOLF•